A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease
This study has been terminated.
(Voluntary halt of further dosing due to an FDA Clinical Hold issued in relation to Dynavax study DV2-HBV-10)
Sponsor:
Dynavax Technologies Corporation
Information provided by:
Dynavax Technologies Corporation
ClinicalTrials.gov Identifier:
NCT00498212
First received: July 5, 2007
Last updated: October 6, 2008
Last verified: October 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | October 2008 |
| Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |